These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 30261554

  • 1. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
    Duong JK, Veal GJ, Nath CE, Shaw PJ, Errington J, Ladenstein R, Boddy AV.
    Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
    [Abstract] [Full Text] [Related]

  • 2. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
    Thomas H, Boddy AV, English MW, Hobson R, Imeson J, Lewis I, Morland B, Pearson AD, Pinkerton R, Price L, Stevens M, Newell DR.
    J Clin Oncol; 2000 Nov 01; 18(21):3614-21. PubMed ID: 11054434
    [Abstract] [Full Text] [Related]

  • 3. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.
    Nath CE, Shaw PJ, Montgomery K, Earl JW.
    Br J Clin Pharmacol; 2005 Mar 01; 59(3):314-24. PubMed ID: 15752378
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.
    Adamson PC, Veal GJ, Womer RB, Meany HJ, Bernhardt MB, Frazier AL, Balis FM.
    Pediatr Blood Cancer; 2019 Jun 01; 66(6):e27672. PubMed ID: 30767382
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ, Errington J, Tilby MJ, Pearson AD, Foot AB, McDowell H, Ellershaw C, Pizer B, Nowell GM, Pearson DG, Boddy AV, UKCCSG Pharmacology Working Group.
    Br J Cancer; 2007 Mar 12; 96(5):725-31. PubMed ID: 17299395
    [Abstract] [Full Text] [Related]

  • 8. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Mar 12; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 9. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
    Kersting G, Willmann S, Würthwein G, Lippert J, Boos J, Hempel G.
    Cancer Chemother Pharmacol; 2012 Feb 12; 69(2):397-405. PubMed ID: 21789689
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep 12; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 12. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
    Newell DR, Eeles RA, Gumbrell LA, Boxall FE, Horwich A, Calvert AH.
    Cancer Chemother Pharmacol; 1989 Sep 12; 23(6):367-72. PubMed ID: 2469544
    [Abstract] [Full Text] [Related]

  • 13. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer.
    Chinnaswamy G, Cole M, Boddy AV, Keir M, Price L, Parry A, English M, Veal GJ, CCLG Pharmacology and Chemotherapy Standardisation Working Groups.
    Br J Cancer; 2008 Sep 16; 99(6):894-9. PubMed ID: 18781149
    [Abstract] [Full Text] [Related]

  • 14. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
    Newell DR, Pearson AD, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR, Stevens MC.
    J Clin Oncol; 1993 Dec 16; 11(12):2314-23. PubMed ID: 8246021
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
    Morrow A, Garland C, Yang F, De Luna M, Herrington JD.
    J Oncol Pharm Pract; 2019 Oct 16; 25(7):1651-1657. PubMed ID: 30336729
    [Abstract] [Full Text] [Related]

  • 18. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
    Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R.
    Aust N Z J Med; 1996 Jun 16; 26(3):372-9. PubMed ID: 8811211
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.
    Veal GJ, Cole M, Errington J, Pearson AD, Gerrard M, Whyman G, Ellershaw C, Boddy AV.
    Cancer Chemother Pharmacol; 2010 May 16; 65(6):1057-66. PubMed ID: 19701749
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.